Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1500243
European Journal of Endocrinology, Vol 150, Issue 3, 243-255
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanstein, B
Right arrow Articles by Bender, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanstein, B
Right arrow Articles by Bender, H.
Articles

Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer

B Hanstein, S Djahansouzi, P Dall, MW Beckmann, and HG Bender

Universitats-Frauenklinik, Heinrich Heine Universitat, Moorenstrasse 5, D-40225 Dusseldorf, Germany. hansteib@uni-duesseldorf.de

Evidence for a role of ovarian factors in the growth of metastatic breast cancer was first recognized over 100 years ago. Today, anti-estrogens are central to the treatment of breast cancer of all stages. We now understand that the action of estrogen is mediated by the estrogen receptors (ER) which are members of the nuclear receptor family of ligand-regulated transcription factors. In this article we review the molecular mechanisms through which ER activates transcription of target genes and through which available anti-estrogens mediate their therapeutic effects. We discuss possible mechanisms of failure of treatment with current anti-estrogens and how newer anti-estrogens under development attempt to address these problems. In addition an expanded view of the molecular mechanisms of estrogen action is leading to the development of novel selective ER modulators or SERMs.


This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola
Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells
J. Mol. Endocrinol., March 1, 2008; 40(3): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Vasudevan and D. W. Pfaff
Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles
Endocr. Rev., February 1, 2007; 28(1): 1 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Howell
Pure oestrogen antagonists for the treatment of advanced breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Giacinti, P. P. Claudio, M. Lopez, and A. Giordano
Epigenetic information and estrogen receptor alpha expression in breast cancer.
Oncologist, January 1, 2006; 11(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
R. Pachlinger, R. Mitterbauer, G. Adam, and J. Strauss
Metabolically Independent and Accurately Adjustable Aspergillus sp. Expression System
Appl. Envir. Microbiol., February 1, 2005; 71(2): 672 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Gold, F. Kalush, J. Bergeron, K. Scott, N. Mitra, K. Wilson, N. Ellis, H. Huang, M. Chen, R. Lippert, et al.
Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk
Cancer Res., December 15, 2004; 64(24): 8891 - 8900.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.